Defined peptide
DSIP or emideltide
Delta sleep-inducing peptide is a short experimental peptide first described in sleep research in the 1970s.
Evidence profile · O-015
DSIP and emideltide: small, historic sleep studies
A sleep-related name is not a proven sleep treatment. DSIP human research is decades old, small and inconsistent, with little meaningful independent development since the original programme.
DSIP, also called emideltide, is not supported by dependable modern evidence for treating insomnia or improving sleep.
Small studies from the 1980s and early 1990s reported mixed changes in sleep measures. A 16-person double-blind study found weak statistical effects that the authors judged unlikely to offer major therapeutic benefit. Later reviews described the sleep-factor hypothesis as poorly documented and unresolved.
Object definition
Two names refer to one experimental peptide
DSIP and emideltide are synonyms, but the peptide, a measured DSIP-like signal and a consumer product remain different objects.
Laboratory signal
DSIP-like immunoreactivity
An assay signal in blood or tissue does not necessarily identify the same active molecule, receptor or therapeutic mechanism.
Consumer object
A vial sold for sleep
A labelled vial does not establish identity, amount, stability, sterility or equivalence to material used in old intravenous studies.
Human evidence
What the small human studies measured
Several experiments reported changes, but the overall programme never produced a robust, replicated clinical answer.
| Evidence object | What was measured | Defensible reading | Main limit |
|---|---|---|---|
| 1981 disturbed-sleep study | Sleep timing and regulation after synthetic DSIP | An early experiment reported a delayed sleep-related signal | Small early study with limited reporting by modern trial standards |
| 1987 severe-insomnia study | Twenty-four-hour sleep-wake behaviour, alertness and performance | One research programme reported sleep and daytime changes | Small sample, old methods and little independent confirmation |
| 1992 double-blind study | Polysomnography, subjective sleep quality and tiredness in 16 people | Some objective measures differed from placebo | Effects were weak, possibly incidental and not reflected in subjective sleep quality |
| 2006 critical review | Identity, gene, receptor and sleep-factor evidence | The original hypothesis remained unresolved | A review cannot replace a new clinical trial, but it documents the stalled evidence base |
Evidence quality
Age matters when evidence has not been revisited
Old evidence is not automatically wrong. Its weight falls when small findings remain unconfirmed despite decades of opportunity.
The DSIP programme used small samples, varied schedules and several sleep or daytime outcomes. Some papers came from overlapping investigators. Positive changes appeared in selected measures rather than as a consistent pattern across objective sleep, subjective sleep quality and daytime function.
The 1992 double-blind study is especially informative because its authors qualified their own result. They noted that significant findings were weak and partly explainable by an incidental placebo-group change. Modern, preregistered replication has not resolved that uncertainty.
Product boundary
Old intravenous studies do not validate a modern sleep vial
The human studies used defined research material and often intravenous administration under laboratory observation. They do not establish what is present in a current vial, how another route changes exposure or whether repeated consumer use is safe.
A certificate may address identity or chromatographic purity if the sample, method and batch are traceable. It cannot bridge missing clinical evidence, show that an old study formulation has been reproduced or establish a safe treatment protocol.
NamesDSIP and emideltide
Core studies1980s to early 1990s
Clinical verdictMajor benefit not established
Modern productEquivalence unknown
Decision boundary
What remains unknown
The research gap is unusually basic: the molecule's role, target and reproducible clinical effect remain unsettled.
- Whether DSIP produces a clinically important improvement in insomnia in a modern, adequately powered trial.
- Which sleep outcome should be treated as primary and whether patients notice a meaningful benefit.
- Whether a specific receptor or reproducible human mechanism explains the early findings.
- The short- and long-term adverse-effect profile under systematic monitoring.
- Whether route and formulation materially change exposure or effects.
- Whether a current product contains the same characterised material used in historic studies.
Evidence ledger
Sources and limits
These records define the conclusions on this page. Each citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| 1981 disturbed-sleep study | An early human experiment reported delayed changes in sleep regulation. | Small early work does not establish durable clinical benefit. | 9 Aug 2026 |
| 1987 severe-insomnia study | A small study measured twenty-four-hour sleep-wake behaviour and daytime outcomes. | The result lacks adequate modern independent confirmation. | 9 Aug 2026 |
| 1987 short-term insomnia study | A double-blind crossover experiment used polysomnography in chronic insomnia. | Small size and short administration prevent a dependable treatment conclusion. | 9 Aug 2026 |
| 1992 double-blind insomnia study | Sixteen participants showed weak changes in selected objective measures. | Authors judged major therapeutic benefit unlikely; subjective sleep quality did not improve. | 9 Aug 2026 |
| 2006 unresolved-riddle review | Documents unresolved questions about DSIP identity, receptor biology and the sleep-factor hypothesis. | A narrative review cannot quantify efficacy or product safety. | 9 Aug 2026 |
Continue the investigation
Read the connected evidence
- the DSIP sleep evidence in contextCompare distinct sleep, cognition and mood claims without treating them as one outcome.
- how we weigh historic evidenceSee how study age, source overlap and absent replication affect confidence.
- the claim-level evidence libraryTrace the sleep verdict to the exact objective and subjective outcomes measured.
- what a certificate cannot establishProduct testing cannot supply missing clinical effectiveness evidence.
Quick answers
Frequently asked questions
Are DSIP and emideltide the same?
Yes. Emideltide is a name used for delta sleep-inducing peptide. A similar name does not prove that a particular vial contains the defined peptide.
Does DSIP improve insomnia?
Dependable modern evidence does not establish a clinically important benefit. Small historic studies produced mixed and weak results.
What did the 1992 double-blind study find?
Some objective sleep measures differed, but effects were weak, possibly incidental and not matched by improved subjective sleep quality. The authors judged major benefit unlikely.
Why does the age of the studies matter?
Age alone does not invalidate a study. Decades without adequate independent replication leave small early findings uncertain and limit confidence in current claims.
Is DSIP a natural sleep hormone?
The proposed sleep-factor role remains poorly documented. Reviews note unresolved questions about its identity, gene, receptor and physiological function.
Can a test certificate prove a DSIP vial will help sleep?
No. A suitable test may address identity or purity in the sampled batch. It cannot establish clinical effectiveness, safe use or equivalence to old study material.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-015, DSIP and emideltide: sleep evidence and study limits was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.